2024
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
Kondo T, Mogensen U, Talebi A, Gasparyan S, Campbell R, Docherty K, de Boer R, Inzucchi S, Køber L, Kosiborod M, Martinez F, Sabatine M, Bengtsson O, Sjöstrand M, Vaduganathan M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial. Journal Of The American College Of Cardiology 2024, 83: 1973-1986. PMID: 38537918, DOI: 10.1016/j.jacc.2024.03.385.Peer-Reviewed Original ResearchConceptsDAPA-HFLeft ventricular ejection fractionNYHA functional class IIEfficacy of dapagliflozinFunctional class IIIV heart failureVentricular ejection fractionEffects of dapagliflozinHeart failure hospitalizationDAPA-HF trialWell-beingFollow-up daysBetween-treatment differencesDapagliflozin groupPlacebo groupTime-to-first-event analysisEjection fractionFailure hospitalizationPatient well-beingHeart failureCardiovascular deathDapagliflozinRecurrent hospitalizationsClass IIPlacebo
2019
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.Peer-Reviewed Original ResearchEMPA-REG OUTCOMEAdverse eventsBoehringer Ingelheim PharmaceuticalsPlasma glucoseMyocardial infarctionCause deathCV outcomesJanssen PharmaceuticalsType 2 diabetes mellitusEli LillyRisk of MIHeart failure hospitalizationRisk of HHFCardio-protective effectsCox regression modelAdvisory PanelCV deathCV diseaseFailure hospitalizationPlacebo groupDiabetes mellitusDohme Corp.Novo Nordisk A/STime-varying covariatesMerck Sharp
2016
LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE
Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.Peer-Reviewed Original ResearchHeart failure hospitalizationHigh cardiovascular riskCardiovascular deathFailure hospitalizationHeart failureStandard of careType 2 diabetesEmpagliflozin groupCardiovascular riskMajor adverse cardiovascular eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEAdverse cardiovascular eventsEffect of empagliflozinHeart failure outcomesMedian observation timeRisk of hospitalizationCardiovascular eventsPlacebo groupAdverse eventsEffect of ageOutcome trialsSafety profileMean ageBaseline age